- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Narrowing Physician Access Puts Pharma in a Bind
Oncologists have a reputation to maintain - and according to the latest report from ZS Associates, when it comes to fortifying against pharmaceutical sales representatives, the specialty remains characteristically hardboiled for the second year in a row.
Oncologists have a reputation to maintain — and according to the latest report from ZS Associates, when it comes to fortifying against pharmaceutical sales representatives, the specialty remains characteristically hardboiled for the second year in a row.
The report consulted 200 different pharmaceutical sales teams within the United States regarding their access to and negotiations with approximately 325,000 physicians and other providers. What analysts soon discovered was that oncologists were considerably more rigorous with setting pharma restrictions and sticking to them than the 20 other common medical specialties, a pattern that began to take shape in the previous years’ studies.
"Today, the average rep can see an oncologist only seven or eight times per year — and even the best reps visit oncologists just once per month," said Ganesh Vedarajan, principal and leader of the oncology and specialty therapeutics practice at ZS Associates, in a prepared statement. "Access has continued to decline due to an increased number of oncology reps trying to reach the doctors and an increasing number of doctors joining institutions that severely restrict rep access."
- See more at: http://www.physbiztech.com/news/business/narrowing-physician-access-puts-pharma-bind#sthash.yy2oWMRD.dpuf
The report consulted 200 different pharmaceutical sales teams within the United States regarding their access to and negotiations with approximately 325,000 physicians and other providers. What analysts soon discovered was that oncologists were considerably more rigorous with setting pharma restrictions and sticking to them than the 20 other common medical specialties, a pattern that began to take shape in the previous years’ studies.
"Today, the average rep can see an oncologist only seven or eight times per year — and even the best reps visit oncologists just once per month," said Ganesh Vedarajan, principal and leader of the oncology and specialty therapeutics practice at ZS Associates, in a prepared statement. "Access has continued to decline due to an increased number of oncology reps trying to reach the doctors and an increasing number of doctors joining institutions that severely restrict rep access."
multiplemyelom
- See more at: http://www.physbiztech.com/news/business/narrowing-physician-access-puts-pharma-bind#sthash.yy2oWMRD.
Oncologists have a reputation to maintain — and according to the latest report from ZS Associates, when it comes to fortifying against pharmaceutical sales representatives, the specialty remains characteristically hardboiled for the second year in a row.Oncologists have a reputation to maintain — and according to the latest report from ZS Associates, when it comes to fortifying against pharmaceutical sales representatives, the specialty remains characteristically hardboiled for the second year in a row.
The report consulted 200 different pharmaceutical sales teams within the United States regarding their access to and negotiations with approximately 325,000 physicians and other providers. What analysts soon discovered was that oncologists were considerably more rigorous with setting pharma restrictions and sticking to them than the 20 other common medical specialties, a pattern that began to take shape in the previous years’ studies.
"Today, the average rep can see an oncologist only seven or eight times per year — and even the best reps visit oncologists just once per month," said Ganesh Vedarajan, principal and leader of the oncology and specialty therapeutics practice at ZS Associates, in a prepared statement. "Access has continued to decline due to an increased number of oncology reps trying to reach the doctors and an increasing number of doctors joining institutions that severely restrict rep access."
Read the full story here: http://bit.ly/13mHHId
Source: PhysBizTech
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
More than 5 years after the American Society of Clinical Oncology warned of emerging disparities in precision medicine, efforts by community practices to embrace technology, form partnerships, and use data show how patients can gain access to personalized approaches. But challenges remain, especially for those covered by Medicaid.
Read More
